BRIEF-GSK says shingles vaccine meets primary endpoint in late-stage trial

* Pivotal phase III study to assess efficacy of HZ/su, an investigational vaccine for prevention of shingles, has met its primary endpoint
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.